Mother-daughter HPV vaccine study in Kenya
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study looks at getting HPV vaccines to Kenyan women ages 25-49 and their daughters ages 9-14. It aims to see how well community meetings work to encourage vaccination and follow-up for the second dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 25 and 49 years old
- You are not pregnant
- You are able to attend community meetings
- Or: you are a girl between 9 and 14 years old and your mother can sign for the vaccine
- Both you and your daughter must be able to return for a second HPV shot in 6 to 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a mobile health tool (an app) and related surveys to improve knowledge and screening awareness for cervical cancer, including HPV risk and acceptability. It involves people working in cervical cancer screening and women in specific communities, with participation based on consent and eligibility for screening.
This study aims to make cervical cancer screening easier and more patient-friendly for women in Kenya. If you are a woman between 25 and 49, not pregnant or recently postpartum, you may be able to join.
This study tests giving the HPV vaccine along with HPV screening to quickly reduce HPV infection and cervical cancer. It is for women aged 23-29 in Rwanda who choose to join.
This trial tests a way to give HPV vaccines along with routine childhood immunizations in Ghana. It aims to protect against HPV, a virus that can cause cervical cancer, by making it easier to get the vaccine.
This study aims to improve how women living with HIV are screened and treated for cervical cancer in Kenya. It involves focus groups and a screening program to find better ways to prevent cancer.
This trial tests if a single dose of a locally made HPV vaccine (CERVAVAC) works as well as a single dose of the standard Gardasil vaccine. It is for girls and young women aged 9 to 20, and boys aged 9 to 14, in Zambia. The goal is to prevent HPV infection, which can cause cervical cancer.
Hear when a new Cervical Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.